• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Baricitinib reduces mortality risk in patients hospitalized with COVID-19

byJessie WillisandTeddy Guo
August 11, 2022
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Baricitinib with usual care was associated with a 13% proportional reduction in mortality compared to treatment as usual care alone.

2. Baricitinib was associated with a higher discharge alive rate and lower progression to mechanical ventilation.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The RECOVERY study has tested multiple promising drug treatments for COVID-19. In this study, RECOVERY assessed baricitinib, a JAK 1-2 inhibitor, in hospitalized patients with suspected or laboratory confirmed COVID-19 for 10 days. The follow-up period was for 28 days or until discharge or death. Baricitinib was found to be associated with a significantly lower mortality rate compared to usual care alone, as well as a higher rate of discharge. Unexpectedly, this 13% proportional reduction of risk was smaller than eight previous trials. Limitations of this study include the open label design and limited follow-up post-discharge. Nonetheless, using these results in an updated meta-analysis, baricitinib has overall been associated with a 20% proportional reduction in mortality (p<0.0001). These results therefore support the use of baricitinib for COVID-19 in hospitalized patients.

Click to read the study in the Lancet

Relevant Reading: Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

In-Depth [randomized controlled trial]: As part of the larger RECOVERY study, this trial evaluated the use of a JAK inhibitor, baricitinib, for the treatment of COVID-19. Eligible patients were greater than age 2 years and had suspected or laboratory confirmed SARS-CoV-2 infection. Enrolled participants were randomized 1:1 to either standard of care alone (n=4008) or standard of care plus baricitinib (n=4148) for 10 days or until discharge. Outcomes were recorded when patients died, were discharged or after 28 days post-randomization. The primary outcome was 28-day all-cause mortality. Follow-up was completed for 99% of patients in both treatment and control groups. Adjusted for age, treatment with baricitinib was associated with a lower mortality rate (rate ratio 0.87, 95% CI 0.77-0.99; p=0.028) compared to treatment as usual. The absolute mortality rate difference was -2% (14% in treatment as usual and 12% in baricitinib group). Discharge rate was also higher in the baricitinib group (1.10, 1.04-1.15). Risk of progression to mechanical ventilation if not on ventilation at baseline was also lowered (0.89, 0.81-0.98). There was no increase in prespecified safety outcomes during the trial.

RELATED REPORTS

Online cooking education may improve perceived cooking and motor competencies in children

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

2 Minute Medicine Rewind January 23, 2023

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: baricitinibCoronavirusCOVID-19JAK1/2 inhibitorSARS-CoV-2
Previous Post

Postoperative and nonoperative atrial fibrillation have a similar risk of associated thromboembolism

Next Post

Prior syncope presentation not associated with increased risk of motor vehicle collision

RelatedReports

Eating in the absence of hunger linked to toddler obesity
Lifestyle

Online cooking education may improve perceived cooking and motor competencies in children

January 31, 2023
Social networks play key roles in parental vaccination decisions
Infectious Disease

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

January 30, 2023
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Weekly Rewinds

2 Minute Medicine Rewind January 23, 2023

January 30, 2023
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Unvaccinated status increases risk of long COVID symptoms

January 25, 2023
Next Post
Steroids and opioids often inappropriately prescribed in the emergency department for pediatric pneumonia and sinusitis

Prior syncope presentation not associated with increased risk of motor vehicle collision

Prasinezumab therapy does not affect Parkinson’s Disease progression

Parents with poor sleep quality report sleep problems in kids

Vitamin D deficiency may be associated with sleep disorders in children

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Extracorporeal and conventional cardiopulmonary resuscitation have similar effects on neurologic outcome in patients with refractory out-of-hospital cardiac arrest
  • Rocatinlimab may be effective in the treatment of moderate-to-severe atopic dermatitis
  • Gender-affirming hormones improve psychosocial functioning in transgender youth
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options